The Dr. Paul Janssen Award for Biomedical Research was established by Johnson & Johnson to honor Dr. Paul Janssen. The Award recipients are chosen by a preeminent and independent selection committee composed of world-leading scientists and clinicians. Intending to acknowledge a scientist whose work has the potential to make a significant, transformational contribution toward the improvement of human health, the Award includes a $100,000 prize and will be given every two years. Dr. Janssen, who was known to his colleagues as Dr. Paul, was one of the 20th century's most gifted and passionate scientists. At the time of his death in 2003, Dr. Paul, who was the founder of Janssen Pharmaceutica, had contributed to the discovery and development of more than 80 medicines that have helped save millions of lives.
"I am very grateful to receive this Award, which aims to extend the legacy of Dr. Paul Janssen, one of the greatest scientific innovators of our time," said Dr. Mello. "I am also very thankful to the Selection Committee for giving me this Award and to be considered alongside so many great scientists."
RNA interference is a biological process where double-stranded RNA inhibits gene expression in a highly specific fashion. Since its discovery in 1998, RNA interference has emerged as a powerful "gene-silencing" technique used in laboratories around the world to determine which genes are important in various diseases and conditions. RNAi also has promise as the basis of gene-silencing therapies. The new field of RNAi-based genomics is a fundamental paradigm shift for biomedical research and has the potential to start a revolution in the development of modern therapeutics.
"Johnson & Johnson is very pleased to award The Dr. Paul Janssen Award for Biomedical Research to Dr. Mello," said William C. Weldon, Chairman, Board of Directors, and Chief Executive Officer of Johnson & Johnson. "His work and research have the potential to help millions of people, and this epitomizes the passion, leadership and innovation that defined Dr. Janssen."
Among Mello's other honors, he has received the 2006 Paul Ehrlich and Ludwig Darmstaedter Prize; the Dr. Lewis S. Rosentiel Award for Distinguished Work in Basic Medical Science; the Gairdner Foundation International Award; the National Academy of Sciences Award in Molecular Biology; the Wiley Prize in Biomedical Sciences; the Warren Triennial Prize, Massachusetts General Hospital; and the Massry Prize.
"Now more than ever, scientific innovation comes at a premium," says Sir Richard Sykes, a member of the Award's international Selection Committee. "Discoveries such as those by Dr. Mello have the potential to open a treasure chest of untold medical innovations that can ultimately help patients on a worldwide basis."
"Dr. Mello is a very deserving recipient of this auspicious award," said Dr. Snyder. "The Committee was faced with a very difficult challenge to select the inaugural recipient for this award. We feel that Dr.Mello's innovative work opens up new pathways to understanding basic biology and will have a true impact on human health."
About The Selection Committee
The Award's independent, international Selection Committee included:
For more information about the Award, please go to http://www.pauljanssenaward.com/.
About Johnson & Johnson
Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 230 Johnson & Johnson operating companies employ approximately 116,000 men and women in 57 countries and sell products throughout the world.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.